EU OKs Mundipharma’s Neulasta biosimilar
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
27th November 2018
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
27th November 2018
Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets.
27th November 2018
New research from Roche UK has revealed that 82% of Generation Z, the age group encompassing 16 to 24 year olds, want to see the NHS introduce digital solutions to better manage their health and improve care.
25th November 2018
The Cell and Gene Therapy (CGT) Catapult has launched the first Advanced Therapy Medicinal Products (ATMP) focused apprenticeship programme, developed in partnership with The Medicine Manufacturing Industry Partnership (MMIP).
25th November 2018
The latest GP workforce figures show a small rise in numbers, which the Royal College of General Practitioners (RCGP) says must be “sustained and accelerated”.
25th November 2018
Second medical use patents have taken a blow with the Supreme Court’s recent ruling in Warner-Lambert v Mylan and Actavis.
For pharmaceutical and life sciences firms, a case-by-case approach to information and content management has been prevalent for too long
We spoke to Medidata’s General Manager and Senior Vice President EMEA Christian Hebenstreit at the New York NEXT conference to find out how virtual trials could change R&D
Tips for becoming compliant
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
This year pharma began to turn its eye towards the power of the microbiome
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma
The true impact of biosimilars is starting to be felt across the industry
...But this year its impact, and the potential for change, was felt across the pharma industry
The biggest cases of the past year
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future
The value and volume of deals in H1 were higher than in the full year 2017, but a slow second half puts us a long way off 2015’s records
Ashfield wants to change the perception of CSOs and their role within pharma
The one consistent theme in today’s market place is complexity
Many of us recognise that we need others’ knowledge to address the opportunities and challenges we face, yet we still lack the time or motivation to collaborate
The connectivity made possible by the Internet of Things (IoT) has provided new opportunities for businesses to put their buildings to work and reap the rewards
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
